Last updated: 2026-09-16 10:31:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Lunai Bioworks Inc. (LNAI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.35, with a market capitalisation of $9.84M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.21 to $13.28. This page covers its latest market performance, valuation, price trends and company information.
$9.84M | |
$2.18 | |
$13.28 | |
$1.21 | |
$2.19 | |
167.00 | |
954.17K | |
-- | |
$13.28 | |
$1.21 | |
-- | |
-- |
Lunai Bioworks Inc. (LNAI) is trading at $2.35 in pre-market trading as of 2026-09-16 10:18:00, up 7.17% ($0.16) from the previous close of $2.19
Pre-market trading shows how investors are pricing LNAI before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Lunai Bioworks Inc. (LNAI) moved from $2.39 to $2.35, representing a decline of 1.80% ($0.04).
The stock traded between $2.10 and $2.93 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 31.95 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 9.4%
LNAI is currently trading at $2.35, placing it 9.4% of the way from its 52-week low of $1.21 to its 52-week high of $13.28. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 29 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Lunai Bioworks Inc. (LNAI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.